AIMS/HYPOTHESIS: Increased glucagon secretion predicts deterioration of glucose tolerance, and high glucagon levels contribute to hyperglycaemia in type 2 diabetes. Inhibition of glucagon action may therefore be a potential novel target to reduce hyperglycaemia. Here, we investigated whether chronic treatment with a glucagon receptor antagonist (GRA) improves islet dysfunction in female mice on a high-fat diet (HFD). MATERIALS AND METHODS: After 8 weeks of HFD, mice were treated with a small molecule GRA (300 mg/kg, gavage once daily) for up to 30 days. Insulin secretion was studied after oral and intravenous administration of glucose and glucagon secretion after intravenous arginine. Islet morphology was examined and insulin secretion and glucose oxidation were measured in isolated islets. RESULTS: Fasting plasma glucose levels were reduced by GRA (6.0 +/- 0.2 vs 7.4 +/- 0.5 mmol/l; p = 0.017). The acute insulin response to intravenous glucose was augmented (1,300 +/- 110 vs 790 +/- 64 pmol/l; p < 0.001). The early insulin response to oral glucose was reduced in mice on HFD + GRA (1,890 +/- 160 vs 3,040 +/- 420 pmol/l; p = 0.012), but glucose excursions were improved. Intravenous arginine significantly increased the acute glucagon response (129 +/- 12 vs 36 +/- 6 ng/l in controls; p < 0.01), notably without affecting plasma glucose. GRA caused a modest increase in alpha cell mass, while beta cell mass was similar to that in mice on HFD + vehicle. Isolated islets displayed improved glucose-stimulated insulin secretion after GRA treatment (0.061 +/- 0.007 vs 0.030 +/- 0.004 pmol islet(-1) h(-1) at 16.7 mmol/l glucose; p < 0.001), without affecting islet glucose oxidation. CONCLUSIONS/ INTERPRETATION: Chronic glucagon receptor antagonism in HFD-fed mice improves islet sensitivity to glucose and increases insulin secretion, suggesting improvement of key defects underlying impaired glucose tolerance and type 2 diabetes.
AIMS/HYPOTHESIS: Increased glucagon secretion predicts deterioration of glucose tolerance, and high glucagon levels contribute to hyperglycaemia in type 2 diabetes. Inhibition of glucagon action may therefore be a potential novel target to reduce hyperglycaemia. Here, we investigated whether chronic treatment with a glucagon receptor antagonist (GRA) improves islet dysfunction in female mice on a high-fat diet (HFD). MATERIALS AND METHODS: After 8 weeks of HFD, mice were treated with a small molecule GRA (300 mg/kg, gavage once daily) for up to 30 days. Insulin secretion was studied after oral and intravenous administration of glucose and glucagon secretion after intravenous arginine. Islet morphology was examined and insulin secretion and glucose oxidation were measured in isolated islets. RESULTS: Fasting plasma glucose levels were reduced by GRA (6.0 +/- 0.2 vs 7.4 +/- 0.5 mmol/l; p = 0.017). The acute insulin response to intravenous glucose was augmented (1,300 +/- 110 vs 790 +/- 64 pmol/l; p < 0.001). The early insulin response to oral glucose was reduced in mice on HFD + GRA (1,890 +/- 160 vs 3,040 +/- 420 pmol/l; p = 0.012), but glucose excursions were improved. Intravenous arginine significantly increased the acute glucagon response (129 +/- 12 vs 36 +/- 6 ng/l in controls; p < 0.01), notably without affecting plasma glucose. GRA caused a modest increase in alpha cell mass, while beta cell mass was similar to that in mice on HFD + vehicle. Isolated islets displayed improved glucose-stimulated insulin secretion after GRA treatment (0.061 +/- 0.007 vs 0.030 +/- 0.004 pmol islet(-1) h(-1) at 16.7 mmol/l glucose; p < 0.001), without affecting islet glucose oxidation. CONCLUSIONS/ INTERPRETATION: Chronic glucagon receptor antagonism in HFD-fed mice improves islet sensitivity to glucose and increases insulin secretion, suggesting improvement of key defects underlying impaired glucose tolerance and type 2 diabetes.
Authors: Anthony Ling; Michael Plewe; Javier Gonzalez; Peter Madsen; Christian K Sams; Jesper Lau; Vlad Gregor; Doug Murphy; Kimberly Teston; Atsuo Kuki; Shenghua Shi; Larry Truesdale; Dan Kiel; John May; James Lakis; Kenna Anderes; Eugenia Iatsimirskaia; Ulla G Sidelmann; Lotte B Knudsen; Christian L Brand; Alex Polinsky Journal: Bioorg Med Chem Lett Date: 2002-02-25 Impact factor: 2.823
Authors: Janice C Parker; Kim M Andrews; Melanie R Allen; Jeffrey L Stock; John D McNeish Journal: Biochem Biophys Res Commun Date: 2002-01-18 Impact factor: 3.575
Authors: Sajjad A Qureshi; Mari Rios Candelore; Dan Xie; Xiaodong Yang; Laurie M Tota; Victor D-H Ding; Zhihua Li; Alka Bansal; Corin Miller; Sheila M Cohen; Guoqiang Jiang; Ed Brady; Richard Saperstein; Joseph L Duffy; James R Tata; Kevin T Chapman; David E Moller; Bei B Zhang Journal: Diabetes Date: 2004-12 Impact factor: 9.461
Authors: Linda Härndahl; Nils Wierup; Sven Enerbäck; Hindrik Mulder; Vincent C Manganiello; Frank Sundler; Eva Degerman; Bo Ahrén; Lena Stenson Holst Journal: J Biol Chem Date: 2004-01-20 Impact factor: 5.157
Authors: Yin Liang; Melville C Osborne; Brett P Monia; Sanjay Bhanot; William A Gaarde; Chantal Reed; Pengxiang She; Thomas L Jetton; Keith T Demarest Journal: Diabetes Date: 2004-02 Impact factor: 9.461
Authors: S E Kahn; R L Prigeon; D K McCulloch; E J Boyko; R N Bergman; M W Schwartz; J L Neifing; W K Ward; J C Beard; J P Palmer Journal: Diabetes Date: 1994-04 Impact factor: 9.461
Authors: Huw B Jones; Jaimini Reens; Simon R Brocklehurst; Catherine J Betts; Sue Bickerton; Alison L Bigley; Richard P Jenkins; Nicky M Whalley; Derrick Morgan; David M Smith Journal: Int J Exp Pathol Date: 2014-02 Impact factor: 1.925
Authors: Seongah Han; Taro E Akiyama; Stephen F Previs; Kithsiri Herath; Thomas P Roddy; Kristian K Jensen; Hong-Ping Guan; Beth A Murphy; Lesley A McNamara; Xun Shen; Walter Strapps; Brian K Hubbard; Shirly Pinto; Cai Li; Jing Li Journal: J Lipid Res Date: 2013-07-04 Impact factor: 5.922
Authors: J Mu; G Jiang; E Brady; Q Dallas-Yang; F Liu; J Woods; E Zycband; M Wright; Z Li; K Lu; L Zhu; X Shen; R Sinharoy; M L Candelore; S A Qureshi; D-M Shen; F Zhang; E R Parmee; B B Zhang Journal: Diabetologia Date: 2011-06-22 Impact factor: 10.122
Authors: Alessandro Pocai; Paul E Carrington; Jennifer R Adams; Michael Wright; George Eiermann; Lan Zhu; Xiaobing Du; Aleksandr Petrov; Michael E Lassman; Guoqiang Jiang; Franklin Liu; Corey Miller; Laurie M Tota; Gaochao Zhou; Xiaoping Zhang; Michael M Sountis; Alessia Santoprete; Elena Capito'; Gary G Chicchi; Nancy Thornberry; Elisabetta Bianchi; Antonello Pessi; Donald J Marsh; Ranabir SinhaRoy Journal: Diabetes Date: 2009-07-14 Impact factor: 9.461